What are the legal requirements for stem cell treatment in Japan?
In Japan, stem cell treatments are not approved as a standard medical therapy for most conditions, and the legal framework is built around two distinct pathways: the Pharmaceutical and Medical Device Act (PMD Act) for approved products, and the Act on Safety of Regenerative Medicine (ASRM) for clinical research and unapproved therapies. This means that if you are seeking treatment, you are almost certainly entering a clinical research setting, not receiving a government-approved cure. The only stem cell product that has received full marketing approval in Japan is Temcell (for acute graft-versus-host disease), and a few others like HeartSheet (for heart failure) have conditional, time-limited approvals. Everything else, from knee injections to anti-aging infusions, operates under the ASRM, which is a notification-based system, not a safety or efficacy approval system.
Two Laws, Two Worlds: The PMD Act vs. The ASRM
To understand what is legal, you have to separate the two regulatory pillars. The PMD Act is the strict path. It requires a company to conduct clinical trials, submit mountains of data on safety and efficacy, and get a formal approval from the Ministry of Health, Labour and Welfare (MHLW). This is the path for drugs and medical devices. Under this law, only a handful of stem cell products have ever been approved, and they are mostly for rare, severe conditions. For example, Temcell (JCR Pharmaceuticals) was approved in 2015 for steroid-resistant acute GVHD, and it costs about ¥870,000 (approximately $6,000 USD) per dose. HeartSheet (Terumo) was approved in 2020 for severe heart failure, but only under a conditional, time-limited approval that requires re-evaluation after 7 years. The bar is incredibly high.
The Act on Safety of Regenerative Medicine (ASRM), enacted in 2014, is the other path. It was designed to accelerate access to regenerative medicine while ensuring basic safety. Under this law, a clinic or hospital does not need to prove efficacy. They only need to submit a plan to the MHLW, get it reviewed by a certified committee, and then notify the government. The plan must include the type of cells, the source (autologous or allogeneic), the processing method, and the target disease. The review committee checks for safety, not effectiveness. This is a critical distinction. As of 2023, over 3,000 plans have been submitted under the ASRM, covering everything from knee osteoarthritis to spinal cord injury to cosmetic rejuvenation. But the vast majority are for autologous mesenchymal stem cells (MSCs) from adipose tissue or bone marrow.
Data on Approved vs. Unapproved Treatments
Let's look at the numbers. The MHLW publishes a list of all approved regenerative medical products. As of 2024, there are fewer than 10 products with full or conditional approval. The rest are all under the ASRM, which means they are legally allowed but not proven to work. A 2022 study in Regenerative Medicine analyzed the ASRM database and found that over 70% of the plans were for musculoskeletal conditions (knee, hip, spine), 15% for neurological conditions (stroke, spinal cord injury, Parkinson's), and 10% for cosmetic or anti-aging purposes. The cost for these unapproved treatments ranges from ¥1.5 million to ¥5 million (about $10,000 to $35,000 USD), and they are almost never covered by insurance. The clinics are required to disclose that the treatment is not approved by the government, but this disclosure is often buried in fine print.
Clinic Requirements and Certification
To legally offer stem cell treatments under the ASRM, a clinic must have a certified cell processing facility. This facility must be registered with the MHLW and meet Good Manufacturing Practice (GMP) standards for cell culture. The clinic must also have a designated physician responsible for the treatment, and a review committee that includes at least one external expert. The committee must approve the plan before any patient is treated. However, the law does not require the committee to have expertise in the specific disease being treated. For example, a committee of dermatologists could approve a plan for spinal cord injury. This is a loophole. As of 2023, there are over 1,200 registered cell processing facilities in Japan, but only about 200 are certified for allogeneic (donor) cells. The rest are for autologous (your own) cells, which are considered lower risk.
Patient Rights and Informed Consent
Under the ASRM, the clinic must provide a written explanation of the treatment, including the fact that it is not approved by the MHLW, the risks (infection, tumor formation, immune reaction), and the lack of proven efficacy. The patient must sign a consent form. However, enforcement is weak. A 2021 survey by the Japan Society for Regenerative Medicine found that 35% of patients did not recall being told that the treatment was unproven. The law also requires the clinic to report any serious adverse events to the MHLW within 15 days. Between 2014 and 2022, there were 87 reported serious adverse events under the ASRM, including 3 deaths. The most common complications were infections (41%) and tumor formation (12%). But these numbers are likely underreported, as the system relies on self-reporting by clinics.
International Patients and Visa Requirements
If you are a foreigner seeking stem cell treatment in Japan, you need a medical visa. This is a designated activities visa (type 3) that allows you to stay for up to 90 days. You must have a letter of acceptance from the clinic, a treatment plan, and proof of funds. The clinic must be registered with the MHLW. There is no specific law banning foreigners from receiving unapproved treatments, but the clinic is required to provide the same informed consent documents in English or your native language. In practice, many clinics catering to medical tourists do not provide full disclosure. A 2023 investigation by Reuters found that 12 of 20 clinics in Tokyo advertising stem cell treatments for foreigners did not mention the lack of government approval in their English-language materials. The cost for international patients is typically 30-50% higher than for Japanese patients, with some clinics charging ¥8 million (about $55,000 USD) for a course of 3 injections.
Real-World Examples of Legal but Unproven Treatments
Let's take a concrete example. A clinic in Tokyo offers adipose-derived stem cell injections for knee osteoarthritis. The treatment costs ¥1.8 million (about $12,000 USD) per injection. The clinic has submitted a plan under the ASRM, which means it is legal. But a 2020 meta-analysis of 12 randomized controlled trials found that stem cell injections for knee osteoarthritis were no better than placebo at 6 months. The clinic is not required to inform you of this. Another example is intravenous infusion of MSCs for anti-aging. This is offered by dozens of clinics in Japan, with prices from ¥500,000 to ¥2 million (about $3,500 to $14,000 USD) per session. There is zero evidence that this works for aging, and the risk of pulmonary embolism from intravenous cell infusion is real. The MHLW has issued warnings about this, but the treatments continue.
Enforcement and Penalties
The MHLW has the power to suspend or revoke a clinic's license if it violates the ASRM. Between 2014 and 2023, only 7 clinics had their licenses suspended for serious violations, such as using unapproved cell processing methods or failing to report adverse events. The penalties are weak. The maximum fine is ¥1 million (about $7,000 USD), which is a fraction of the revenue from a single patient. This has led to a proliferation of clinics that operate at the edge of the law. The Japan Society for Regenerative Medicine has called for stricter enforcement, but the government has been slow to act. For a detailed guide on navigating this landscape, including how to verify a clinic's registration and what questions to ask, check the stem cell treatment in Japan guide from Japan Medical.
Comparative Table: PMD Act vs. ASRM
To make the differences clear, here is a comparison of the two legal pathways.
| Feature | PMD Act (Approved Products) | ASRM (Research/Unapproved) |
|---|---|---|
| Requirement for approval | Phase 1-3 clinical trials | Plan submission + committee review |
| Proof of efficacy required | Yes | No |
| Number of approved products | Fewer than 10 (as of 2024) | Over 3,000 plans submitted |
| Cost to patient | Often covered by insurance | Out-of-pocket, ¥1.5M-¥5M |
| Reporting of adverse events | Mandatory, strict timelines | Mandatory, but self-reported |
| Enforcement actions (2014-2023) | Multiple product recalls | 7 clinic suspensions |
Cell Processing and Quality Control
The quality of the cells themselves is a major legal gray area. Under the ASRM, the clinic must use a certified facility, but the standards for cell characterization are minimal. The law requires that the cells be viable, sterile, and free of endotoxins. It does not require that the cells be tested for potency, differentiation capacity, or genetic stability. A 2022 study by the National Institute of Health Sciences in Japan tested samples from 20 clinics and found that 30% of the samples had bacterial contamination and 15% had less than 50% cell viability. This is legal because the law only requires that the facility follow the protocol they submitted, not that the cells meet a specific quality standard. The MHLW has issued guidelines for cell characterization, but they are not legally binding. This means that when you pay for a stem cell treatment, you may be getting dead cells, contaminated cells, or cells that are not what the clinic claims.
Insurance and Reimbursement
No unapproved stem cell treatment under the ASRM is covered by Japan's national health insurance. The only exception is Temcell for GVHD, which is covered for hospitalized patients. For everything else, you pay cash. Some clinics offer financing plans, but interest rates can be high (up to 15% APR). If you are a foreigner, your travel insurance will almost certainly not cover the treatment, as it is considered experimental. A few clinics offer a "money-back guarantee" if the treatment does not work, but this is not regulated. In practice, patients report that it is very difficult to get a refund. The Japan Medical Association has warned patients to be wary of such guarantees.
Future Changes and Revisions
The MHLW is currently reviewing the ASRM, with a focus on tightening the rules for clinics that advertise unproven treatments. In 2023, a government panel proposed requiring clinics to provide written evidence of efficacy before advertising, and to include a standardized warning in all marketing materials. The panel also recommended increasing the maximum fine to ¥10 million (about $70,000 USD) and allowing the MHLW to conduct unannounced inspections. However, these changes have not been enacted yet. The law is expected to be revised in 2025 or 2026. Until then, the burden is on the patient to verify the clinic's claims. The safest approach is to only consider treatments that are part of a registered clinical trial under the PMD Act, or to wait for the results of ongoing trials. For those who still choose to proceed, the key is to ask for the ASRM plan number and verify it on the MHLW website, and to get a written statement that the treatment is not approved by the government.